Binding proteins, population and individual variability, assay techniques and biases
Plasma protein binding measurements are an essential part of drug metabolism and pharmacokinetics (DMPK) and ADME studies, as it influences efficacy, dosing, clearance, half-life and drug interactions.
While the methods to assess plasma binding of drugs have been largely standardized, evidence from clinical studies suggests that standard approaches fail to answer several critical issues.
Dr. Hinnerk Boriss,
CEO
Hinnerk is CEO and owner of Sovicell GmbH. He's been working in drug discovery for over 10 years and has over 25 years of experience science at the interface of math and biology and developed several clinical diagnostic tests and biochemical assays. His specialty is assay development through a combination of mathematical modeling of assay conditions and wet-lab validation. He received his education in biochemistry, theoretical physics and biostatistics from the University of Göttingen, Germany, the University of California Davis, the Max Planck Institute for Limnology and Stanford University.
- Factors contributing to individual and population variation in plasma protein binding
- Review of clinical evidence highlighting the significance of plasma binding variation
- Measurement and modelling strategies to assess and predict plasma binding across different populations and diseases
- Technological advances that enable accurate measurements of binding to individual plasma proteins as well as peptide binding
- Group Leaders
- Lab Heads
- Scientist
- Technology Managers
- Innovation Manager
- Head of Preclinical R&D
